Dupilumab biosimilar (Bio-Thera Solutions)

度普利尤单抗生物类似药 (百奥泰生物)

Report date: 2025/10/30 14:36:32

First In Class

Base Information

Drug NameDupilumab biosimilar (Bio-Thera Solutions)

Drug Alias NameDupilumabum biosimilar度匹鲁单抗生物类似药 (百奥泰生物)度匹芦人单抗 (百奥泰生物)重组全人源抗IL-4Rα单克隆抗体BAT2406 +[6]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanBiologics > Biosimilar

Mechanisms of ActionInterleukin-4 receptor subunit alpha inhibitorsInterleukin-4 inhibitorsInterleukin-13 inhibitors

TargetsInterleukin-4 receptor subunit alphaInterleukin-4Interleukin-13

Therapy Area/IndicationsPrurigo NodularisDermatitis, AtopicNasal Polyps +[6]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsPrurigo NodularisDermatitis, AtopicNasal Polyps +[6]

Inactive IndicationsN/A

ATC CodeN/A